Madrigal Pharmaceuticals (NASDAQ:MDGL) and Corbus Pharmaceuticals (NASDAQ:CRBP) Head to Head Survey

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and Corbus Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	12.47	-$288.28 million	($12.87)	-40.30
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.98)	-1.76

Corbus Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Madrigal Pharmaceuticals and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-30.08%	-43.76%	-24.88%
Corbus Pharmaceuticals	N/A	-65.76%	-57.88%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Madrigal Pharmaceuticals and Corbus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	3	12	1	2.76
Corbus Pharmaceuticals	2	0	7	2	2.82

Madrigal Pharmaceuticals presently has a consensus price target of $685.31, suggesting a potential upside of 32.13%. Corbus Pharmaceuticals has a consensus price target of $43.88, suggesting a potential upside of 317.06%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Insider & Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.